Skip to content

Study · Observational study · n = 292 · 2024

7 results

Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?

Formichi C, Baronti W, de Gennaro G, Cerrai Ceroni M, Nigi L, Rizzo L, Dotta F

Journal of endocrinological investigation29 Apr 2024Cited by 11 (Europe PMC)

PMID38683498 (opens in a new tab)PMCIDPMC11473455 (opens in a new tab)DOI10.1007/s40618-024-02369-4 (opens in a new tab)PepBankPUB-38683498
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

PurposeTo evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects.MethodsWe retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.ResultsOral semaglutide was preferentially prescribed in older subjects with longer disease duration in replacement of other antidiabetic drugs, while subcutaneous semaglutide was preferentially prescribed in add-on to metformin in subjects with higher body weight and BMI. After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction. No differences were found in terms of adverse events.ConclusionIn our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, both oral and subcutaneous semaglutide significantly improved glycemic control after 6 months.

    In plain wordsIn adults with type 2 diabetes, both oral and injected semaglutide improved blood sugar control after 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycemic control after 6 months, both formulations
    Study

    n = 292

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral and subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, both oral and subcutaneous semaglutide significantly improved body weight after 6 months.

    In plain wordsIn adults with type 2 diabetes, both oral and injected semaglutide improved body weight after 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight after 6 months, both formulations
    Study

    n = 292

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral and subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide reduced A1c more than oral semaglutide after 6 months.

    In plain wordsIn a real-world study of adults with type 2 diabetes, injected semaglutide was linked to a larger A1c fall than the oral form.

    Peptide
    Semaglutide
    Outcome
    DecreaseA1c reduction, subcutaneous versus oral
    Study

    n = 292

    Comparator
    Oral semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide produced greater weight loss than oral semaglutide after 6 months.

    In plain wordsIn a real-world study of adults with type 2 diabetes, injected semaglutide was linked to more weight loss than the oral form.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, subcutaneous versus oral
    Study

    n = 292

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide reduced BMI more than oral semaglutide after 6 months.

    In plain wordsIn a real-world study of adults with type 2 diabetes, injected semaglutide was linked to a larger BMI fall than the oral form.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction, subcutaneous versus oral
    Study

    n = 292

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide reduced waist circumference more than oral semaglutide after 6 months.

    In plain wordsIn a real-world study of adults with type 2 diabetes, injected semaglutide was linked to a larger waist size fall than the oral form.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference reduction, subcutaneous versus oral
    Study

    n = 292

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
  7. 07HumanObservational studySafety outcome

    No differences in adverse events were found between oral and subcutaneous semaglutide.

    In plain wordsOral and injected semaglutide had no difference in side effects in this study.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse events, oral versus subcutaneous
    Study

    n = 292

    Comparator
    Oral versus subcutaneous semaglutide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral and subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No differences were found in terms of adverse events.
    1 context sentence
    Summary · context
    We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.